View Item 

Show simple item record

Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers

dc.contributor.authorElnachef, N.en_US
dc.contributor.authorScheiman, James M.en_US
dc.contributor.authorFendrick, A. Marken_US
dc.contributor.authorHowden, C. W.en_US
dc.contributor.authorChey, William D.en_US
dc.date.accessioned2010-06-01T21:43:53Z
dc.date.available2010-06-01T21:43:53Z
dc.date.issued2008-11en_US
dc.identifier.citationELNACHEF, N.; SCHEIMAN, J. M.; FENDRICK, A. M.; HOWDEN, C. W.; CHEY, W. D. (2008). "Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers." Alimentary Pharmacology & Therapeutics 28(10): 1249-1258. <http://hdl.handle.net/2027.42/74775>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74775
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18729848&dopt=citationen_US
dc.format.extent157353 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rightsJournal compilation © 2008 Blackwell Publishing Ltden_US
dc.titleChanging perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providersen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* Division of Gastroenterology, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationum† Division of General Internal Medicine, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationother† Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, IL, USAen_US
dc.identifier.pmid18729848en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74775/1/j.1365-2036.2008.03836.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2008.03836.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceSingh G, Triadafilopoulos G. Epidemiology of NSAID-induced gastrointestinal complications. J Rheumatol 1999; 26 ( Suppl. 26 ): 18 – 24.en_US
dc.identifier.citedreferenceU.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002; 136: 157 – 60.en_US
dc.identifier.citedreferencePearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke, 2002 updated. Consensus panel guide to comprehensive risk reductionh for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388 – 91.en_US
dc.identifier.citedreferenceBaron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131: 1674 – 82.en_US
dc.identifier.citedreferenceMahmud SM, Tanguay S, Begin LR, Franco EL, Aprikian AG. Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev 2006; 15: 158 – 64.en_US
dc.identifier.citedreferenceVaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s esophagus: a prospective study. Lancet Oncol 2005; 6: 945 – 52.en_US
dc.identifier.citedreferenceBrun J, Jones R. Nonsteroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med 2001; 110: 12S – 3S.en_US
dc.identifier.citedreferenceLanas A, Panes J, Pique JM. Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Des 2003; 9: 2253 – 66.en_US
dc.identifier.citedreferenceSilverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory durgs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241 – 9.en_US
dc.identifier.citedreferenceLane ME, Kim MJ. Assessment and prevention of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. J Pharm Pharmacol 2006; 58: 1295 – 304.en_US
dc.identifier.citedreferenceWilcox CM, Allison J, Benzuly K, et al. Consensus Development Conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 2006; 4: 1082 – 9.en_US
dc.identifier.citedreferenceWolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888 – 99.en_US
dc.identifier.citedreferenceWatson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. Curr Med Res Opin 2004; 20: 1539 – 48.en_US
dc.identifier.citedreferenceLanas A, Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 2006; 38: 415 – 28.en_US
dc.identifier.citedreferenceHawkey CJ, Weinstein WM, Smalley W, et al. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. Gastroenterology 2007; 133: 57 – 64.en_US
dc.identifier.citedreferenceGoldstein JL, Eisen GM, Agrawal N, et al. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther 2004; 20: 527 – 38.en_US
dc.identifier.citedreferenceWong D, Wang M, Cheng Y, FitzGerald G. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr Opin Pharmacol 2005; 5: 204 – 10.en_US
dc.identifier.citedreferenceSolomon SD, Wittes J, Finn PV, et al. Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117: 2104 – 13.en_US
dc.identifier.citedreferenceMcGettigan P, Henry D. Cardiovascular risk and inhibition of cycloxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633 – 44.en_US
dc.identifier.citedreferenceKearny PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammtory drugs increase the risk of atherothrombosis? Meta-analys of randomized trials. BMJ 2006; 332: 1302 – 8.en_US
dc.identifier.citedreferenceAbraham NS, Hartman C, Castillo D, Richardson P, Smalley W. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol 2008; 103: 323 – 32.en_US
dc.identifier.citedreferenceChey WD, Eswaren S, Howden CW, Inadomi JM, Fendrick AM, Scheiman JM. Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey. Aliment Pharmacol Ther 2006; 23: 655 – 68.en_US
dc.identifier.citedreferenceCampbell C, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardivoascular disease. A systematic review. JAMA 2007; 297: 2018 – 24.en_US
dc.identifier.citedreferenceHuang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14 – 22.en_US
dc.identifier.citedreferenceLaine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with traditional NSAID or coxib use. Gastroenterol 2003; 124: 288 – 92.en_US
dc.identifier.citedreferenceSilverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247 – 55.en_US
dc.identifier.citedreferenceCatella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809 – 17.en_US
dc.identifier.citedreferenceMacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573 – 4.en_US
dc.identifier.citedreferenceWeisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162: 2191 – 202.en_US
dc.identifier.citedreferenceWeil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 311: 259 – 60.en_US
dc.identifier.citedreferenceLanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834 – 9.en_US
dc.identifier.citedreferenceDerry S, Loke YK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033 – 88.en_US
dc.identifier.citedreferenceSanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 2001; 85: 265 – 71.en_US
dc.identifier.citedreferencePatrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001; 119 ( Suppl ): 39S – 63S.en_US
dc.identifier.citedreferenceLaine L. Review article: gastrointestinal bleeding with low-dose aspirin – what’s the risk? Aliment Pharmacol Ther 2006; 24: 897 – 908.en_US
dc.identifier.citedreferenceLai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033 – 8.en_US
dc.identifier.citedreferenceTargownik LE, Metge CJ, Leung S. Underutilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications. Aliment Pharmacol Ther 2008; 28: 88 – 96.en_US
dc.identifier.citedreferenceSorensen HT, Mellmkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95: 2218 – 24.en_US
dc.identifier.citedreferenceDe Abajo FJ, Rodriquez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001; 1: 1. Epub 2001 Feb 13.en_US
dc.identifier.citedreferenceKelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413 – 6.en_US
dc.identifier.citedreferenceHernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Int Med 2000; 160: 2093 – 9.en_US
dc.identifier.citedreferenceChan F. Management of high-risk patients on non-steroidal anti-inflammatory drugs or asprin. Drugs 2006; 66 ( Suppl. 1 ): 23 – 8.en_US
dc.identifier.citedreferenceCatella-Lawson F, Reilly M, Kapoor S, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809 – 17.en_US
dc.identifier.citedreferenceKimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142: 157 – 64.en_US
dc.identifier.citedreferenceHippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2036.2008.03836.x.pdf
Size:
153.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.